Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-Center, Open-Label, Single-Arm Clinical Study of Sequential Anti-BCMA CAR-T Cell Therapy Following Autologous Hematopoietic Stem Cell Transplantation in Transplant-Eligible Newly Diagnosed Multiple Myeloma

NCT06913192 is registered in ClinicalTrials.gov with Xuzhou Medical University as lead sponsor.

NCT NCT06913192
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06913192 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-Center, Open-Label, Single-Arm Clinical Study of Sequential Anti-BCMA CAR-T Cell Therapy Following Autologous Hematopoietic Stem Cell Transplantation in Transplant-Eligible Newly Diagnosed Multiple Myeloma
Lead sponsor
Xuzhou Medical University
Phase
Phase 1
Overall status
Not yet recruiting
Start date
April 1, 2025
Completion date
February 28, 2028
Enrollment
50 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma